Get the Stockscreener App
14.92
5.07%
0.72
Benitec Biopharma Inc stock is traded at $14.92, with a volume of 67,094.
It is up +5.07% in the last 24 hours and up +11.84% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$14.20
Open:
$14.09
24h Volume:
67,094
Relative Volume:
1.19
Market Cap:
$391.66M
Revenue:
$59,000
Net Income/Loss:
$-21.81M
P/E Ratio:
-1.3623
EPS:
-10.9518
Net Cash Flow:
$-18.07M
1W Performance:
+7.80%
1M Performance:
+11.84%
6M Performance:
+24.96%
1Y Performance:
+52.09%
1-Day Range:
$14.09
$15.31
1-Week Range:
$13.54
$15.31
52-Week Range:
$9.10
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
14.92 | 372.76M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
Will Benitec Biopharma Inc. stock go up soonWeekly Risk Report & Community Consensus Picks - newser.com
Is Benitec Biopharma Inc a good long term investmentEquity Performance Review & Trusted Financial Advisors at No Cost - earlytimes.in
What’s the recovery path for long term holders of Benitec Biopharma Inc.July 2025 Sentiment & Stepwise Trade Execution Plans - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Benitec Biopharma (NASDAQ:BNTC) - MarketBeat
What Fibonacci levels say about Benitec Biopharma Inc. reboundJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - newser.com
Benitec Biopharma (NASDAQ:BNTC) Stock Rating Lowered by Zacks Research - MarketBeat
Using Ichimoku Cloud for Benitec Biopharma Inc. technicals2025 Fundamental Recap & High Accuracy Investment Signals - newser.com
Is Benitec Biopharma Inc. stock reversal real or fake2025 Volatility Report & Free Technical Confirmation Trade Alerts - newser.com
Intraday pattern recognizer results for Benitec Biopharma Inc.2025 Support & Resistance & Safe Entry Trade Signal Reports - newser.com
What indicators show strength in Benitec Biopharma Inc.July 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
Leading vs lagging indicators on Benitec Biopharma Inc. performanceGap Down & Comprehensive Market Scan Insights - newser.com
Will Benitec Biopharma Inc. see short term momentumJuly 2025 News Drivers & Consistent Growth Stock Picks - newser.com
Where Analysts See Genomic Valley Biotech Limited Stock by YearEndMonthly Performance Summary & Bull Bear Market Updates - earlytimes.in
Published on: 2025-10-03 03:21:02 - newser.com
Backtesting results for Benitec Biopharma Inc. trading strategiesSwing Trade & Weekly Hot Stock Watchlists - newser.com
Applying big data sentiment scoring on Benitec Biopharma Inc.Bull Run & Free Safe Entry Trade Signal Reports - newser.com
Benitec Biopharma Limited (NASDAQ:BNTC) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Published on: 2025-09-30 04:03:09 - newser.com
How to build a custom watchlist for Benitec Biopharma Inc.Bull Run & Fast Momentum Entry Tips - newser.com
How to interpret RSI for Benitec Biopharma Inc. stockQuarterly Trade Review & Risk Controlled Daily Plans - newser.com
Published on: 2025-09-29 09:23:28 - newser.com
Published on: 2025-09-29 08:12:02 - newser.com
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Benitec Biopharma Inc Stock (BNTC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Mar 26 '25 |
Buy |
13.00 |
900,000 |
11,700,000 |
8,793,245 |
| BUCHI J KEVIN | Director |
Feb 27 '25 |
Option Exercise |
3.86 |
51,813 |
199,998 |
103,910 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 23 '24 |
Buy |
10.98 |
27,502 |
301,972 |
7,981,725 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 24 '24 |
Buy |
11.25 |
20,018 |
225,202 |
7,999,455 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Dec 03 '24 |
Buy |
9.60 |
42,000 |
403,200 |
7,957,365 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 20 '24 |
Buy |
10.22 |
27,436 |
280,396 |
7,920,175 |
| SUVRETTA CAPITAL MANAGEMENT, L | Director |
Nov 19 '24 |
Buy |
9.73 |
14,000 |
136,220 |
7,895,815 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):